Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 14/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778660 | 1.00 | GRIN2B (0.46) | GRIN2BCCR1PROKR1NPC1LMNA | |
| SCHEMBL6774775 | 0.86 | PRMT5 (0.48) | GRIN2BCCR1NPC1MAPTRAB9A | |
| SCHEMBL6777723 | 0.86 | PRMT5 (0.48) | GRIN2BCCR1NPC1MAPTRAB9A | |
| SCHEMBL6774773 | 0.86 | PRMT5 (0.48) | GRIN2BCCR1NPC1MAPTRAB9A | |
| SCHEMBL7113404 | 0.86 | HRH3 (0.44) | LMNATP53MAPTKCNH2 | |
| SCHEMBL7113402 | 0.86 | HRH3 (0.44) | LMNATP53MAPTKCNH2 | |
| SCHEMBL7536178 | 0.86 | HRH3 (0.44) | LMNATP53MAPTKCNH2 | |
| SCHEMBL6774355 | 0.84 | ACACB (0.47) | GRIN2BSMN1; SMN2 | |
| SCHEMBL6774352 | 0.84 | ACACB (0.47) | GRIN2BSMN1; SMN2 | |
| SCHEMBL6778334 | 0.83 | TACR1 (0.45) | PROKR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831078-B1 | 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant | VERNALIS RESEARCH LIMITED (GB) | 2004-12-14 | — | — | US | claimed |
| EP-1049670-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2002-07-17 | — | — | EP | claimed |
| EP-1049670-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | claimed |
| WO-1999037613-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | claimed |
| US-6831078-B1 | 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant | VERNALIS RESEARCH LIMITED (GB) | 2004-12-14 | — | — | US | disclosed |
| EP-1049670-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS | VERNALIS RES LTD (GB) | 2002-07-17 | — | — | EP | disclosed |
| EP-1196165-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007022-A2 | AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |